Ekso Bionics Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2826443010
USD
4.07
-0.53 (-11.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Ekso Bionics Holdings, Inc. stock-summary
stock-summary
Ekso Bionics Holdings, Inc.
Pharmaceuticals & Biotechnology
Ekso Bionics Holdings, Inc., formerly PN Med Group, Inc., designs, develops and sells wearable bionic human exoskeletons that have applications in healthcare, industrial, military and consumer markets. The Company operates through two segments: Engineering Services and Medical. The Engineering Services segment is engaged in collaborative research and development service arrangements, technology license agreements and government grants where it uses its robotics domain knowledge in bionic exoskeletons to bid on and procure contracts and grants from entities, such as the National Science Foundation and the Defense Advanced Research Projects Agency. The Medical segment designs, engineers and manufactures exoskeletons for applications in the medical and military markets. The Company's exoskeleton systems are worn over the user's clothing. The exoskeleton systems serve various markets, which can be used both by able-bodied users, as well as by persons with physical disabilities.
Company Coordinates stock-summary
Company Details
1414 Harbour Way S Ste 1201 , RICHMOND CA : 94804-3628
stock-summary
Tel: 1 510 98417611 212 8671768
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (3.67%)

Foreign Institutions

Held by 9 Foreign Institutions (4.75%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Steven Sherman
Executive Chairman of the Board
Mr. Jack Peurach
President, Chief Executive Officer, Director
Ms. Mary Cloyd
Director
Ms. Rhonda Wallen
Director
Dr. Theodore Wang
Director
Ms. Marilyn Hamilton
Independent Director
Dr. Charles Li
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 11 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

-101.87%

stock-summary
Price to Book

0.98